Evidence map›Paper›PMID 39576390›Full record

ArticleClinical and experimental nephrology2025

Pharmacological inhibition of the NLRP3 inflammasome attenuates kidney apoptosis, fibrosis, and injury in Dahl salt-sensitive rats.

Yue Wang, Yuhang Wu, Jiayu Ren, Ying Wang, Imran Perwaiz, Hongtong Su, Jing Li, Peng Qu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue Wang *Institute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Yuhang Wu *Institute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Jiayu RenInstitute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Ying WangInstitute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Imran PerwaizInstitute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Hongtong SuInstitute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Jing Li *Institute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China.
Peng Qu *Institute of Heart and Vessel Diseases, The Second Hospital Affiliated of Dalian Medical University, Dalian, 116000, China. 3121907398@qq.com.ORCID http://orcid.org/0009-0002-3795-3975

Funding

Doctoral Start-up Foundation of Liaoning Province 2019-BS-065National Natural Science Foundation of China 81900223National Natural Science Foundation of China 91739119United Fund of the Second Hospital of Dalian Medical University and Dalian Institute of Chemical Physics, Chinese Academy of Sciences UF-QN-202006
6 · The paper itself

Abstract

backgroundSalt-sensitive hypertension (SSH) is the most severe form of hypertension, and the presence of NLRP3 inflammasome plays a crucial role in its pathogenesis. Although MCC950 has shown therapeutic potential for hypertension and kidney injury, its mechanism of action remains unclear.

methodsDahl salt-sensitive (SS) rats and their salt-tolerant aptamer control SS-13

resultsCompared with the SS + vehicle group, the SS + MCC950 group showed significantly lower blood pressure levels. Additionally, inhibition of NLRP3 inflammasome activation was observed along with reduced inflammation, apoptosis, fibrosis, and sodium retention in the kidneys.

conclusionsThe findings suggest that pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure in SS rats and alleviates related kidney injury by suppressing inflammation, apoptosis, fibrosis, and sodium retention.

Indexed as

ApoptosisFuransHypertensionInflammasomesKidneyKidney DiseasesNLR Family, Pyrin Domain-Containing 3 ProteinSulfonamidesSulfonesAnimalsBlood PressureCyclopropanesDisease Models, AnimalFibrosisIndenesMaleCyclopropanesFuransIndenesInflammasomesN-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamideNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratSulfonamidesSulfonesKidney injuryMCC950NLRP3 inflammasomeRatsSalt-sensitive hypertension

Identifiers

PMID39576390
PMCPMC11807026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.